<DOC>
	<DOC>NCT02048709</DOC>
	<brief_summary>This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.</brief_summary>
	<brief_title>Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically or cytologically confirmed solid tumor that is relapsed/refractory to standard therapies or for which no approved or curative therapy exists Age &gt; or = 18 Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2 Life expectancy &gt; or = 12 weeks Adequate hematologic and organ function before initiation of GDC0919 For some patients only: Accessible lesions amenable to paired fresh tumor biopsies Some prior cancer immunotherapies Untreated brain metastases Active or history of autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>